# Semnur Pharmaceuticals

**Canonical:** https://apis.io/providers/semnur-pharmaceuticals/  
**Website:** https://semnurpharma.com  
**APIs profiled:** 0

Semnur Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing non-opioid pain-management therapies. Its lead program, SP-102 (SEMDEXA), is a novel, non-opioid, preservative-free and particulate-free injectable corticosteroid gel formulation intended to treat moderate-to-severe chronic radicular pain (sciatica). Semnur is a subsidiary of Scilex Holding Company and is headquartered in the San Francisco Bay Area, California. As a pharmaceutical R&D company it publishes a corporate website, investor presentation, and scientific publications, but exposes no public developer API, documentation, or SDK surface.

## Kin Score — 2.2 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.2).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Pharmaceuticals, Biopharmaceutical, Healthcare, Pain Management, Non-Opioid, Clinical Stage, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/semnur-pharmaceuticals/). Scores are computed from the provider's own public artifacts under a published rubric.